-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, CSPC announced to license the global rights of Claudin12 ADC new drug SYSA1801 outside of Greater China to Elevation Oncolo.
CSPC Jushi Bio will receive a down payment of US$27 million and has the right to receive up to Potential development and regulatory milestone payments of $148 million and potential sales milestone payments of $02 billion, as well as a high-to-double-digit sales sha.
In addition, on July 26, Kelun Pharmaceuticals just announced that it has reached a research and development cooperation and license agreement with Merck & .
for ADC drugs (Project B) for the treatment of solid tumors, involving a total amount of over 900 million US dolla.
It is understood that before this, Kerun Botai, a subsidiary of Kerun Pharmaceutical, has authorized Project A to Merck, and the total authorized amount of the two projects is as high as 3 billion US dolla.
The reason why Kelun Pharmaceutical has made a lot of progress in the ADC field is that Kelun Botai has established an ADC platform with independent intellectual property rights very ear.
The author learned that the company has more than 10 ADC projects in different stages, and has the GMP production capacity from target discovery, toxicological linker screening, design and ADC full platfo.
Three of the ADC drugs are already in the clinical research stage, including SKB264, A166 and SKB-315; Nectin-4 ADC is expected to apply for IND in QThe continuous export of ADC products of the above companies is actually a microcosm of the accelerated development of the domestic ADC indust.
It is understood that at the moment when domestic innovative drug companies are blocked from "going overseas", in less than a year, five ADC drugs from local companies have been "going overseas" one after another, targeting CD30, HER2, CD22, Trop -2, with a total transaction value of nearly $7 billi.
ADC is an antibody-conjugated drug, which refers to an innovative drug composed of antibodies, toxins and linkers, which can precisely deliver toxins to tumor cells to play a killing effe.
In recent years, many domestic and foreign pharmaceutical companies are racing to devel.
According to data from Southwest Securities, from 2019 to 2021, a total of 9 ADC drugs have been launched in the world, more than the sum of the previous nearly two decad.
Entering 2022, the number of ADC drugs approved worldwide at the beginning of the year has reached 14, and more than 150 are in the clinical development sta.
According to the market forecast of Nature's sub-issue, by 2026, the global ADC drug market will reach 14 billion US dolla.
With the continuous entry of domestic pharmaceutical companies in the field of ADC drugs, the results have begun to emerge, and the number of new domestic ADC drugs that have been authorized overseas is also increasing, and the amount of cooperation is hu.
For example, in August 2021, Rongchang Bio announced that it had reached an exclusive global license agreement with Seagen for the development and commercialization of Vidicitum.
Under the agreement, Rongchang Biotech will receive up to $6 billion in total potential revenue from the transacti.
On May 5 this year, Lixin Pharma also announced that it has reached an exclusive licensing agreement with Turning Point in the United Stat.
The latter will act as an exclusive partner to obtain the innovative antibody-drug conjugate (ADC) LM-302 independently developed by Lixin Phar.
Development and commercialization rights in countries and regions other than Greater China and South Korea, involving a total amount of over US$1 billi.
Industry analysts believe that although the research on ADCs of domestic pharmaceutical companies started late, there are now many players and the results are accelerati.
In the future, under this background, the overseas authorization of domestic pharmaceutical companies in the ADC field is expected to achieve more new breakthroug.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
CSPC Jushi Bio will receive a down payment of US$27 million and has the right to receive up to Potential development and regulatory milestone payments of $148 million and potential sales milestone payments of $02 billion, as well as a high-to-double-digit sales sha.
In addition, on July 26, Kelun Pharmaceuticals just announced that it has reached a research and development cooperation and license agreement with Merck & .
for ADC drugs (Project B) for the treatment of solid tumors, involving a total amount of over 900 million US dolla.
It is understood that before this, Kerun Botai, a subsidiary of Kerun Pharmaceutical, has authorized Project A to Merck, and the total authorized amount of the two projects is as high as 3 billion US dolla.
The reason why Kelun Pharmaceutical has made a lot of progress in the ADC field is that Kelun Botai has established an ADC platform with independent intellectual property rights very ear.
The author learned that the company has more than 10 ADC projects in different stages, and has the GMP production capacity from target discovery, toxicological linker screening, design and ADC full platfo.
Three of the ADC drugs are already in the clinical research stage, including SKB264, A166 and SKB-315; Nectin-4 ADC is expected to apply for IND in QThe continuous export of ADC products of the above companies is actually a microcosm of the accelerated development of the domestic ADC indust.
It is understood that at the moment when domestic innovative drug companies are blocked from "going overseas", in less than a year, five ADC drugs from local companies have been "going overseas" one after another, targeting CD30, HER2, CD22, Trop -2, with a total transaction value of nearly $7 billi.
ADC is an antibody-conjugated drug, which refers to an innovative drug composed of antibodies, toxins and linkers, which can precisely deliver toxins to tumor cells to play a killing effe.
In recent years, many domestic and foreign pharmaceutical companies are racing to devel.
According to data from Southwest Securities, from 2019 to 2021, a total of 9 ADC drugs have been launched in the world, more than the sum of the previous nearly two decad.
Entering 2022, the number of ADC drugs approved worldwide at the beginning of the year has reached 14, and more than 150 are in the clinical development sta.
According to the market forecast of Nature's sub-issue, by 2026, the global ADC drug market will reach 14 billion US dolla.
With the continuous entry of domestic pharmaceutical companies in the field of ADC drugs, the results have begun to emerge, and the number of new domestic ADC drugs that have been authorized overseas is also increasing, and the amount of cooperation is hu.
For example, in August 2021, Rongchang Bio announced that it had reached an exclusive global license agreement with Seagen for the development and commercialization of Vidicitum.
Under the agreement, Rongchang Biotech will receive up to $6 billion in total potential revenue from the transacti.
On May 5 this year, Lixin Pharma also announced that it has reached an exclusive licensing agreement with Turning Point in the United Stat.
The latter will act as an exclusive partner to obtain the innovative antibody-drug conjugate (ADC) LM-302 independently developed by Lixin Phar.
Development and commercialization rights in countries and regions other than Greater China and South Korea, involving a total amount of over US$1 billi.
Industry analysts believe that although the research on ADCs of domestic pharmaceutical companies started late, there are now many players and the results are accelerati.
In the future, under this background, the overseas authorization of domestic pharmaceutical companies in the ADC field is expected to achieve more new breakthroug.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
